Oligonucleotide Synthesis Market Report 2025

The oligonucleotide synthesis market size has grown rapidly in recent years. It will grow from $10.33 billion in 2024 to $11.94 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to growth in biomedical research advancements, therapeutic development, biotechnology innovations, genomic studies, and increasing DNA technologies.

The oligonucleotide synthesis market size is expected to see rapid growth in the next few years. It will grow to $22.29 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to emerging diagnostic tools, RNA interference (RNAi) therapies, regenerative medicine, nanotechnology applications, and advancements in gene editing. Major trends in the forecast period include targeted drug development, innovative delivery systems, automated synthesis, CRISPR-cas technology, and next-generation sequencing (NGS).

The projected growth in the oligonucleotide synthesis market is expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, characterized by lasting one year or longer and requiring ongoing medical attention, are a global health concern. Oligonucleotides play a crucial role in addressing chronic diseases by acting on gene expression through various mechanisms. They can target mRNA, pre-mRNA, or non-coding RNA to modulate splicing events, induce degradation, or interfere with protein translation. For instance, the global prevalence of diabetes is projected to increase by 12.2% in 2045, reaching 536.6 million individuals in the 20-79 age group, as reported by the International Diabetes Federation in January 2022. Additionally, chronic diseases, including cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, contribute to a significant percentage (74%) of global non-communicable disease-related deaths, with 41 million deaths annually, according to the World Health Organization in September 2022. This rising prevalence of chronic and rare diseases is a key driver fueling the growth of the oligonucleotide synthesis market.

The increasing demand for personalized medicine is expected to contribute to the market's growth. Personalized medicine, also known as precision medicine, leverages an individual's genetic and molecular profile to tailor prevention and treatment strategies. Oligonucleotide synthesis plays a vital role in developing precision medicines by providing small-molecule drugs composed of synthetically modified RNA or DNA strands that target specific cellular processes. The Personalized Medicine Coalition (PMC) reported in October 2022 that there will be over 75,000 genetic testing products and 300 personalized medicines on the market, catering to individuals with various types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. The increasing demand for personalized medicine is thus identified as a significant driver for the oligonucleotide synthesis market's growth.

Product innovation is a significant trend gaining traction in the oligonucleotide synthesis market. Key companies are focusing on developing innovative products to maintain their competitive edge in the market. For example, in July 2024, Ansa Biotechnologies, Inc., a US-based manufacturer of complex DNA, introduced Ansa Clonal DNA and Ansa DNA Fragments. Ansa Clonal DNA delivers clonal, sequence-perfect DNA up to 600 base pairs in length, removing the need for assembly and providing unmatched accuracy for complex synthetic biology projects. This product guarantees error-free, ready-to-use DNA sequences, making it a dependable option for researchers. Ansa DNA Fragments offers sequence-verified linear double-stranded DNA fragments, also up to 600 base pairs, designed for various research applications. Through its innovative enzymatic synthesis process, Ansa consistently produces complex DNA constructs, including repeats and secondary structures, with high precision.

Major companies in the oligonucleotide synthesis market are focusing on introducing novel synthesis techniques, such as de novo synthesis, to gain a competitive edge. In March 2023, Ansa Biotechnologies, a U.S.-based biotechnology company, achieved a significant milestone by successfully de novo synthesizing the longest oligonucleotide in the world, comprising 1005 bases. This sequence encodes a crucial part of an Adeno-Associated Virus (AAV) vector used in gene therapy development. Overcoming challenges related to strong secondary structures and high GC content, this achievement allows for the direct synthesis of gene-length sequences, impacting the fields of genetic engineering and biotechnology.

In June 2024, GSK plc, a UK-based pharmaceutical company, acquired Elsie Biotechnologies for $50 million. This acquisition enables GSK to fully incorporate Elsie’s technologies for oligonucleotide discovery, synthesis, and delivery into its research and development framework. This integration is anticipated to bolster GSK's current capabilities in creating oligonucleotide-based medicines. Elsie Biotechnologies is a US-based firm specializing in oligonucleotide therapeutics.

Major companies operating in the oligonucleotide synthesis market include Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Nitto Denko Avecia Inc., Alnylam Pharmaceuticals Inc., Maravai Life Sciences, LGC Limited, Ionis Pharmaceuticals Inc., GenScript Inc., Ajinomoto Bio-Pharma Services, Sarepta Therapeutics Inc., Integrated DNA Technologies Inc., Twist Bioscience Corporation, Eurogentec SA, Kaneka Eurogentec S.A., Biocomma Limited, Bio-Synthesis Inc., TriLink BioTechnologies Incorporated, Generi Biotech s.r.o., ATDBio Ltd., BioAutomation Corporation, Biolegio B.V., Dharmacon Research Inc.

North America was the largest region in the oligonucleotide synthesis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oligonucleotide synthesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oligonucleotide synthesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oligonucleotide synthesis refers to the chemical process of linking nucleotides in a precise sequence, resulting in the formation of a desired product. This method is widely utilized in modern laboratory practices, providing a rapid and cost-effective means to obtain customized oligonucleotides with specific sequences.

There are two primary types of oligonucleotide synthesis, custom oligos and predesigned oligos. Custom oligos are produced through solid-phase chemical synthesis, where the nucleic acids A, T, C, and G are sequentially added to create a chain of nucleotides. The range of products involved in this process includes oligonucleotides, reagents, equipment, services, purification, and modification. These products find applications in various fields, such as therapeutic applications, research applications, and diagnostic applications. Oligonucleotide synthesis is a versatile tool that plays a crucial role in creating tailored genetic sequences for diverse purposes in the scientific and medical communities.

The oligonucleotide synthesis market research report is one of a series of new reports that provides oligonucleotide synthesis market statistics, including oligonucleotide synthesis industry global market size, regional shares, competitors with a oligonucleotide synthesis market share, detailed oligonucleotide synthesis market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide synthesis industry. This oligonucleotide synthesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oligonucleotide synthesis market consists of revenues earned by entities by providing non-coding RNA inhibition, splicing modulation, gene activation, and programmed gene editing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oligonucleotide synthesis market also includes sales of RNAi oligonucleotides, antisense oligonucleotides, condensation activators, sulphur-transfer reagents, and deprotection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.